RxDoctor Payments Data

Darshan Dave, MD

Internal Medicine · Leland, NCNPI 1285052639

Payments from drug & device makers

$1,177in general payments, 2019–2025

Across 13 payments — averaging $90.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$673
  • Novo Nordisk$207
  • Amgen$124
  • Boehringer Ingelheim$116
  • Lilly USA, LLC$57

What the payments were for

  • Food & beverage$1,177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$673
Novo Nordisk2$207
Amgen1$124
Boehringer Ingelheim1$116
Lilly USA, LLC2$57

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,177 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$584,320
Medicare patients
770
Services billed
22,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol28$41,991
OzempicSemaglutide15$41,939
JardianceEmpagliflozin37$40,867
TrulicityDulaglutide13$22,529
JanuviaSitagliptin Phosphate11$16,950
InvokanaCanagliflozin16$12,491
Atorvastatin Calcium1,003$11,099
SynthroidLevothyroxine Sodium135$10,969
Levothyroxine Sodium935$9,787
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$9,401
NexletolBempedoic Acid16$9,309
Ezetimibe384$9,252
Rosuvastatin Calcium686$8,096
Repatha SureclickEvolocumab11$7,344
Pravastatin Sodium302$4,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$673$41,99128 claims
Novo NordiskOzempic$207$41,93915 claims
Boehringer IngelheimJardiance$116$40,86737 claims
Lilly USA, LLCTrulicity$57$22,52913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Leland

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →